NCT02262832View on ClinicalTrials.gov

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 9, 2014

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
LipodystrophyDiabetesHyperlipidemia
Interventions
DRUG

Metreleptin

administered subcutaneously 1-2 times/day

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH